Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting®
October 21, 2022 01:00 ET
|
Sequana Medical NV
Presentation by Dr. Florence Wong on Sunday November 6th in Washington, DC:“An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent...
Sequana Medical announces H1 2022 results and provides business update
September 08, 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION8 September 2022, 07:00 CET alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON...
Sequana Medical Notice of 2022 Half Year Results and Business Update
September 01, 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 1 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease,...
Alexandra Clyde appointed to Sequana Medical Board of Directors
August 25, 2022 01:00 ET
|
Sequana Medical NV
Seasoned medtech leader with more than 30 years’ healthcare experience Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer...
Sequana Medical secures EUR 10 million loan facility with Kreos Capital
July 20, 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION20 July 2022, 07:00 CET Company’s cash runway extended into Q3 2023 Ghent, Belgium – 20 July 2022 – Sequana Medical NV (Euronext Brussels:...
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update
July 19, 2022 01:02 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION19 July 2022, 07:00 am CEST DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA Ii with...
Doug Kohrs appointed to Sequana Medical Board of Directors
July 19, 2022 01:00 ET
|
Sequana Medical NV
Highly experienced US medtech leader brings more than 40 years’ experience Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a...
Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
May 27, 2022 12:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION27 May 2022, 06:00 pm CEST Ghent, Belgium – 27 May 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the...
Sequana Medical announces Annual and Extraordinary General Meetings of Shareholders on 27 May 2022
April 27, 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION27 April 2022, 07:00 am CEST Publication of Annual Report 2021 Ghent, Belgium – 27 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or...
Sequana Medical announces 2021 Full Year Results and 2022 Outlook
April 12, 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION12 April 2022, 07:00 CET alfapump® in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months...